Alkermes plc
Rank #232DeclineALKS · Nasdaq · Healthcare
Alkermes plc (ALKS) — Rank #232 by gross profitability (GP/assets 0.29) · ROE 13.4% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001520262 · all metrics point-in-time as of the filing date.
About
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Show moreShow less
The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- alkermes.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-25 | 2024-12-31filed 2025-02-12 | 2023-12-31filed 2024-02-21 | 2022-12-31filed 2023-02-16 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 27.2 | 28.5 | 74.9 | 77.9 |
| Stock-based compensation | 98.7 | 96.6 | 100.9 | 94.3 |
| Change in inventory | 14.1 | (3.1) | 2.7 | 31.0 |
| Operating cash flow | 520.8 | 439.1 | 401.4 | 21.0 |
| Investing | ||||
| Capital expenditures | 40.4 | 33.5 | 48.0 | 38.3 |
| Acquisitions, net of cash | — | — | — | — |
| Investing cash flow | 295.5 | (111.3) | 53.4 | (64.5) |
| Financing | ||||
| Debt issued | — | — | — | — |
| Debt repaid | — | 2.3 | 3.0 | 3.0 |
| Share repurchases | — | 200.3 | — | — |
| Financing cash flow | 12.4 | (494.1) | (289.7) | (1.6) |
| Summary | ||||
| Free cash flow | 480.3 | 405.6 | 353.3 | (17.2) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?